On November 6, 2026 Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs targeting oncological and inflammatory diseases, reported its participation in BIO-Europe 2026, taking place November 9–11 in Cologne, Germany, with additional digital partnering sessions scheduled for November 17–18. BIO-Europe 2026.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Dr. Sari Fishman, Vice President of Business Development, will represent Can-Fite at the conference, focusing on potential licensing agreements, co-development arrangements, commercialization partnerships, and other strategic transactions aimed at unlocking the commercial value of the Company’s advanced clinical pipeline.
Can-Fite enters BIO-Europe following a series of clinical and intellectual property developments that have strengthened its portfolio and expanded potential partnering opportunities across multiple therapeutic areas.
Key assets and partnering opportunities include:
• Namodenoson – Pancreatic Cancer: Final positive Phase IIa results, presented at ESMO (Free ESMO Whitepaper) 2026, demonstrated a favorable safety profile and encouraging exploratory survival findings in heavily pretreated patients, supporting further clinical development.
• Namodenoson – Liver Cancer: An ongoing pivotal Phase III study in advanced hepatocellular carcinoma (HCC), with longer-than-anticipated blinded overall survival observed across the study population. An interim analysis is planned.
• Piclidenoson – Psoriasis: A pivotal Phase III program that has reached its prespecified interim analysis stage, with results expected in the first quarter of 2027.
• Namodenoson – MASH: An ongoing Phase IIb clinical development program targeting a significant global market opportunity.
• Piclidenoson – Lowe Syndrome: A rare disease development program supported by a collaboration with Fondazione Telethon and recently strengthened by a Eurasian patent allowance covering Lowe syndrome and Dent disease 2.
Can-Fite has already established multiple regional licensing agreements, generating approximately $20 million in upfront and milestone payments to date, with the potential for additional milestones and royalties. The Company intends to build on this commercial track record by pursuing additional regional and broader strategic partnerships.
"BIO-Europe provides an important opportunity to translate our recent clinical and intellectual property progress into strategic business discussions," said Dr. Sari Fishman, Vice President of Business Development at Can-Fite BioPharma. "With two pivotal Phase III programs, encouraging new clinical data in pancreatic cancer, and an expanding portfolio of development and commercialization opportunities, we believe Can-Fite offers potential partners access to differentiated clinical-stage assets across several major therapeutic markets. Our objective is to pursue licensing and strategic collaborations that can accelerate development, expand global commercialization opportunities, and create long-term value for our shareholders."
BIO-Europe is one of the biopharmaceutical industry’s leading international partnering events, bringing together pharmaceutical companies, biotechnology developers, investors, and business development executives from around the world.
Dr. Fishman will be available for partnering discussions throughout the conference.
(Press release, Can-Fite BioPharma, NOV 6, 2026, View Source [SID1234674388])